Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Double-Blind Study to Evaluate the Safety and Tolerability of AV-1980R in Participants With Preclinical Alzheimer's Disease

Next Previous
Trial Profile

A Phase I, Randomized, Double-Blind Study to Evaluate the Safety and Tolerability of AV-1980R in Participants With Preclinical Alzheimer's Disease

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AV-1980R (Primary) ; Adjuvants
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man
  • Acronyms TAURUS-1980

Most Recent Events

  • 08 Sep 2025 Status changed from planning to not yet recruiting.
  • 07 Dec 2021 New trial record
  • 22 Nov 2021 According to an Institute for Molecular Medicine media release, the company has recently completed using the NIA funding and is currently on track for this phase 1 study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top